Workflow
麦角硫因陷多重争议,究竟是有效产品还是营销噱头?
2 1 Shi Ji Jing Ji Bao Dao·2025-06-06 08:37

Core Viewpoint - The controversy surrounding ergothioneine, a compound linked to anti-aging, has intensified following accusations of it being a "fake drug" due to lack of sufficient evidence for its approval as a medicine. Companies like Kelun Pharmaceutical and its subsidiary have defended ergothioneine's classification as a health management tool rather than a drug, citing international studies that support its potential benefits [1][2][4]. Industry Overview - The global market for ergothioneine is projected to exceed $810.4 million by 2027, with a compound annual growth rate (CAGR) of 36.17% from 2021 to 2027. The raw material market for ergothioneine is also expected to grow from $6.3 million in 2024 to $16.1 million by 2031 [1]. - Companies such as Huaxi Biological and Chuaning Biological are accelerating their production capabilities through synthetic biology to meet the rising demand for high-purity ergothioneine [2][8]. Product Positioning and Pricing - Ergothioneine is marketed as a dietary supplement rather than a drug, with Kelun's product priced at 1499 yuan for 60 capsules, while competitors like Jinsan Biological offer similar products at 539 yuan. Kelun justifies its pricing based on Japanese market standards and production costs [4][5]. - The compound is recognized as a fifth-generation antioxidant and is used in both topical and oral applications, often combined with other ingredients like hyaluronic acid and collagen peptides [3][6]. Scientific Research and Development - Despite claims of ergothioneine's anti-aging effects, there are gaps in scientific understanding regarding its mechanisms and clinical validation. Research indicates that while ergothioneine shows promise, further studies are needed to explore its effects and applications in medicine [2][8]. - Companies are investing in research to better understand ergothioneine's potential, with Huaxi Biological planning to invest 1.35 million yuan in related projects [7]. Production and Supply Chain - The production of ergothioneine has historically faced challenges due to low yields from natural sources, but advancements in synthetic biology are enabling domestic companies to increase production capacity. For instance, Chuaning Biological plans to establish a facility capable of producing 0.5 tons of ergothioneine annually [6][8]. - The majority of ergothioneine is produced through microbial fermentation or enzyme catalysis, with domestic firms achieving over 99% purity in their products [8].